ArticleClinical Medicine Insights. Oncology2021

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).

Melissa Bersanelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.